Clinical Trial Update: Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Modalities [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating anti-CEA antibody immunoscintigraphy combined with PET to localize recurrent colorectal cancer in patients with rising CEA bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anti-CEA antibody immunoscintigraphy agent

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Neoplasm | Phase 2 | Status: COMPLETED